In a remarkable case, Penn Medicine researchers used an AI-driven platform to identify adalimumab—a drug already approved for other conditions—as a life-saving treatment for a patient with idiopathic multicentric Castleman’s disease (iMCD).

New research reveals how nighttime breathing patterns can uncover Parkinson’s disease with remarkable accuracy, even years before diagnosis. This non-invasive breakthrough not only enables earlier detection but also tracks symptom progression, promising a transformative approach to managing Parkinson’s worldwide.